Literature DB >> 8687256

The Lyme disease controversy. Social and financial costs of misdiagnosis and mismanagement.

L H Sigal1.   

Abstract

Since it was first described, Lyme disease has emerged as a major public health concern, complicated by an emerging body of beliefs often at odds with scientifically established facts. Disagreement between the belief systems has led to confusion and anxiety, resulting in an alternative, but unproved, approach to management. When Lyme disease is incorrectly diagnosed, the debility related to the true, underlying problems remains unaddressed. The financial cost of the overdiagnosis and overtreatment of Lyme disease includes expenses related to testing and therapy and those of side effects and toxic effects of these treatments. Harder to estimate are the emotional costs to society of incorrectly burdening patients with the diagnosis of a chronic, incurable illness, with attendant assumption of a sick role and a disabled self-image. Better education is a major component of the solution to the problems of misdiagnosis and mistreatment of Lyme disease.

Entities:  

Mesh:

Year:  1996        PMID: 8687256     DOI: 10.1001/archinte.156.14.1493

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  13 in total

1.  Patterns of Lyme disease diagnosis and treatment by family physicians in a southeastern state.

Authors:  John M Boltri; Robert B Hash; Robert L Vogel
Journal:  J Community Health       Date:  2002-12

2.  Lyme disease: How reliable are serologic results?

Authors:  Dan Gregson; G Evans; David Patrick; William Bowie
Journal:  CMAJ       Date:  2015-08-31       Impact factor: 8.262

3.  Psychiatric comorbidity and other psychological factors in patients with "chronic Lyme disease".

Authors:  Afton L Hassett; Diane C Radvanski; Steven Buyske; Shantal V Savage; Leonard H Sigal
Journal:  Am J Med       Date:  2009-09       Impact factor: 4.965

4.  Lymelight: forecasting Lyme disease risk using web search data.

Authors:  Adam Sadilek; Yulin Hswen; John S Brownstein; Evgeniy Gabrilovich; Shailesh Bavadekar; Tomer Shekel
Journal:  NPJ Digit Med       Date:  2020-02-04

5.  In vitro activities of the everninomicin SCH 27899 and other newer antimicrobial agents against Borrelia burgdorferi.

Authors:  L L Dever; C V Torigian; A G Barbour
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

6.  Use of serum immune complexes in a new test that accurately confirms early Lyme disease and active infection with Borrelia burgdorferi.

Authors:  M Brunner; L H Sigal
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

7.  Appropriateness of Lyme disease serologic testing.

Authors:  Alan H Ramsey; Edward A Belongia; Po-Huang Chyou; Jeffrey P Davis
Journal:  Ann Fam Med       Date:  2004 Jul-Aug       Impact factor: 5.166

Review 8.  Medically unexplained symptoms: exacerbating factors in the doctor-patient encounter.

Authors:  L A Page; S Wessely
Journal:  J R Soc Med       Date:  2003-05       Impact factor: 18.000

9.  Evaluating frequency, diagnostic quality, and cost of Lyme borreliosis testing in Germany: a retrospective model analysis.

Authors:  I Müller; M H Freitag; G Poggensee; E Scharnetzky; E Straube; Ch Schoerner; H Hlobil; H-J Hagedorn; G Stanek; A Schubert-Unkmeir; D E Norris; J Gensichen; K-P Hunfeld
Journal:  Clin Dev Immunol       Date:  2011-12-27

Review 10.  Contributions of societal and geographical environments to "chronic Lyme disease": the psychopathogenesis and aporology of a new "medically unexplained symptoms" syndrome.

Authors:  Leonard H Sigal; Afton L Hassett
Journal:  Environ Health Perspect       Date:  2002-08       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.